# Andrew B. Lassman

Source: https://onco.cc/people/andrew-lassman/  
OnCo record `andrew-lassman` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival.

## Summary

Andrew Lassman is chief of neuro-oncology at Columbia University Irving Medical Center. He was the lead investigator and first author of the 2023 Neuro-Oncology report of INTELLANCE-1, the phase 3 trial of depatuxizumab mafodotin added to radiotherapy and temozolomide in EGFR-amplified newly diagnosed glioblastoma, which showed no overall survival benefit despite earlier promise. He leads several cooperative-group glioma trials.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: brain; trialist
- Role: Chief of Neuro-Oncology, Columbia University Irving Medical Center
- Specialisms: Glioblastoma; Antibody-drug conjugates; Neuro-oncology trials

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- institutions: [Herbert Irving Comprehensive Cancer Center, Columbia University](https://onco.cc/institutions/columbia-hicc/)
- trials: [INTELLANCE-1](https://onco.cc/trials/intellance-1/)

---
JSON: https://onco.cc/api/v1/entities/andrew-lassman.json